안구 통증 : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Eye Pain Market Outlook

Thelansis's "Eye Pain Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Eye Pain treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Eye Pain Overview

Eye pain encompasses sharp, aching, or pressure-like discomfort arising from ocular or periocular structures, driven by corneal irritation, intraocular inflammation, raised pressure, or referred neuropathic signals. Key symptoms include photophobia, redness, tearing, and visual disturbance. Diagnosis relies on slit-lamp examination, tonometry, and fluorescein staining, with IOP elevation or anterior chamber flare indicating severity. First-line management targets the underlying cause: antibiotics for infection, steroids for inflammation, and pressure-lowering agents for glaucoma. Monitoring visual acuity and IOP guides escalation. With timely care, prognosis is generally favorable; sudden vision loss warrants urgent referral.

Key Highlights

• In France, females account for a larger share of the eye pain patient population (54.1%) compared with males (45.9%).
• Ocular surface disorders, infections, trauma, and inflammatory conditions remain major contributors to eye pain burden.
• Increasing healthcare utilization and ophthalmology consultations are supporting improved diagnosis and management.
• Chronic and recurrent ocular conditions continue to impact patient quality of life and productivity.
• Growing adoption of targeted ophthalmic therapies is improving symptom management outcomes.

Market Overview

• The France eye pain market is projected to grow from approximately $231.8 MN in 2025 to $323.0 MN by 2035.
• Market growth is supported by:
• Increasing prevalence of ocular surface and inflammatory eye disorders
• Growing utilization of prescription ophthalmic treatments
• Expansion of specialized eye care services is supporting treatment uptake.
• Future growth will depend on innovative anti-inflammatory and pain-targeted ophthalmic therapies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Bausch & Lomb Incorporated
• Surface Ophthalmics, Inc.
• Biogen
• Oculis
• iRenix Medical, Inc.
• Frisch Medical Device Private Limited

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)